Drug Profile

PRX 115

Alternative Names: PRX-115; Recombinant PEGylated Uricase - Protalix Biotherapeutics; Recombinant uricase - Protalix Biotherapeutics

Latest Information Update: 26 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protalix BioTherapeutics
Class Antigouts; Enzymes; Polyethylene glycols; Recombinant proteins
Mechanism of Action Urate oxidase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Gout

Most Recent Events

23 Dec 2024 Protalix completes a phase I trials in Gout in New Zealand (IV) (NCT05745727)
14 Nov 2024 Protalix Biotherapeutics plans a phase II trial for Gout in second half of 2025
14 Nov 2024 Pharmacodynamics data from a phase 1 trial in Gout presented at the ACR Convergence 2024 (ACR-2024) .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com